Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksYGEN.L Regulatory News (YGEN)

  • There is currently no data for YGEN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATE

7 Apr 2010 07:00

RNS Number : 7878J
ViaLogy PLC
07 April 2010
 



VIALOGY PLC ("VIALOGY" OR "THE COMPANY")

TRADING UPDATE

 

London, April 7, 2010. ViaLogy (LSE: VIY). The board of ViaLogy announces that the fiscal year ending March 31, 2010, marks a year of strong performance highlighted by the successful introduction of QuantumRD seismic analysis and reservoir characterization technology to the hydrocarbon energy market. ViaLogy ends the year with 12 clients under contract, including two key industry independent E&P firms, and a strong sales pipeline which should produce additional high quality Exploration and Production company customers in the coming months. The five successfully completed wells have demonstrated the ability of QuantumRD to locate productive hydrocarbon deposits in a variety of formations.ViaLogy's strategy going forward is to work closely with clients to exercise the technology in as yet untried areas of major significance, especially to bring QuantumRD to shale gas and offshore exploration plays. ViaLogy's work for contracted clients has produced an inventory contingent backlog of over 60 probable future wells to be drilled at locations recommended by ViaLogy. The Company stresses that the ultimate decision to drill, drilling schedules, and locations are dependent upon clients' operational plans, as are business decisions about the timing of hydrocarbon extraction.

The five successful well completions have been at widely separated locations in Texas ranging from 3,000 ft to 12,000 ft in depth. These targeted structural and stratigraphic formations include carbonates, vugs, clastic sediments and channel sands. The deliverables provided analysis of formation porosity, lithology and fluid presence.

ViaLogy'stechnical staff now includes experienced and industry geophysical specialists, and two to three more will join the staff in the coming months. In addition, ViaLogy will establish a Houston office to accelerate business development objectives and maintain close access to the customer base.

ViaLogy has ambitious objectives for the coming year. The focus will be on additional strong customers and repeat business, further establishing the Company's business model where payment is received through substantial up-front service fees and a share of income from successful wells. It should be emphasized that while QuantumRD - based on proprietary active signal processing technology that uniquely exploits signal spectrum and associated noise to extract more, and more precise, information from seismic data - will not prove successful in 100 per cent. of cases, it should significantly de-risk exploration as compared with current industry methods.

The coming months should see drilling of four to five new ViaLogy-positioned wells, some with new and some with established clients, and that number will increase over the course of the coming year. In its latest project, San Antonio-based client Atascosa is currently determining whether to do a deviated drilling completion of its Escondido well or to drill at another nearby ViaLogy designated location. Initial results indicate that the drilling process may have failed to achieve the placement accuracies set by ViaLogy, but has confirmed that QuantumRD analysis accurately located a pay zone and determined porosity. It is always up to the operator to determine if the expense of well completion is justified by the operator-estimated amount of profitably extractable oil, i.e. the standard he sets for his own operating margins. Atascosa's other two producing wells will be reworked in the coming months to bring them up to optimal production; such rework is typical and may include installation of larger pump and cement squeeze into the formations.

CEO Robert Dean said, "I'm very pleased that we've been able to achieve as much as we have during the last year. Anyone with experience will tell you unabashedly that you have to prove yourself to win acceptance in the oil industry, and that it doesn't come easily. Also, it's not academic - it's about finding oil. ViaLogy has done this in very challenging situations. We have successfully completed a significant number of QuantumRD wells, and, very significantly, our retrospective analysis showed why previous drilling efforts had produced dry holes for over 20 wells. The technology's ability to accurately and repeatably predict the presence of hydrocarbons and to estimate porosity are two of the critical variables in the high-risk exploration world. We are building our team of industry professionals and we can now look forward to a major year that brings ViaLogy to another level of industry acceptance for our pathbreaking QuantumRD."

 

For further information please contact:

 

ViaLogy plc

Robert W Dean, President & CEO - US +1 626-296-6337 (mobile: +1 703-589-3807)

Terry Bond, Chairman - UK & Europe +44 (0) 1235-834734 (mobile: 07860 842756)

 

Nominated Advisor to ViaLogy PLC (Seymour Pierce)

Mark Percy / Catherine Leftley, Corporate Finance +44 (0) 20-7107-8000

Jeremy Stephenson / Katie Ratner, Corporate Broking +44 (0) 20-7107-8000

 

 

About ViaLogy: Network Centric Signal Processing

ViaLogy is a leading innovator of network-centric, real-time signal processing platforms for sensor applications. ViaLogy is currently deploying and designing computational systems, powered by its patented technologies, for applications in life sciences, public safety and security, surveillance, defense and geoseismology. ViaLogy focuses on market driven problems where automation, timeliness, quality and reliability of information processing are essential. ViaLogy's core competency incorporates rapidly and accurately detecting weak signals buried in high noise background and clutter. This technology can be employed to solve problems involving sensor integration and information overload challenges involving video, telephony and control sensors, as well as for enhancement of numerous signal processing applications. For more information, visit our website at www.ViaLogy.com. Except for statements of historical fact, the information presented herein constitutes forwardlooking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
TSTQQLFBBZFXBBZ
Date   Source Headline
1st Apr 201912:12 pmRNSHolding(s) in Company
25th Mar 20197:00 amRNSYourgene raises IONA® test awareness in Egypt
26th Feb 20193:21 pmRNSHolding(s) in Company
22nd Feb 201910:00 amEQSHardman & Co Research: Yourgene Health (YGEN): EBITDA-positive in fiscal 2020
22nd Feb 20198:05 amRNSHolding(s) in Company
19th Feb 20192:21 pmRNSHolding(s) in Company
19th Feb 20197:15 amEQSHardman & Co Research: Yourgene Health (YGEN): Transformed and de-risked
18th Feb 201910:59 amRNSIssue of Equity
18th Feb 20197:00 amRNSMajor Capital & Commercial Restructuring
8th Jan 20197:00 amRNSYourgene launches Sage 32 plex
3rd Dec 20187:00 amRNSHalf-year Results
7th Nov 20187:00 amRNSChange of Name to Yourgene Health plc
5th Nov 201811:24 amRNSShare Transfer
2nd Nov 20187:00 amRNSDirectorate Change
25th Oct 20183:30 pmRNSResult of AGM
25th Oct 20187:00 amRNSHolding(s) in Company
25th Oct 20187:00 amRNSAGM Statement
22nd Oct 20187:00 amRNSFurther re: Fundraise
12th Oct 20181:15 pmRNSAvailability of Research Commentary
12th Oct 20187:00 amRNSTrading Update and Notice of Results
5th Oct 20187:00 amRNSDirector's dealing and share option issue
4th Oct 20187:00 amRNS$1 million collaboration agreement
3rd Oct 20187:00 amRNSDirectorate change
2nd Oct 20187:00 amRNSNotice of AGM
1st Oct 201812:20 pmRNSResult of Fundraise
28th Sep 20185:41 pmRNSProposed fundraise to raise approximately £2.5m
28th Sep 20185:40 pmRNSFull year results and half-year trading update
25th Sep 201811:31 amRNSHolding(s) in Company
21st Sep 20184:10 pmRNSHolding(s) in Company
21st Sep 20187:00 amRNSHolding(s) in Company
20th Sep 20189:30 amRNSSenior Appointment & Anticipated Director Change
19th Sep 201811:05 amRNSSecond Price Monitoring Extn
19th Sep 201811:00 amRNSPrice Monitoring Extension
19th Sep 20187:00 amRNSLegal Settlement & Licence Agreement with Illumina
11th Sep 20187:00 amRNSHolding(s) in Company
7th Aug 201810:57 amRNSHolding(s) in Company
12th Jul 20187:00 amRNSShare option awards
4th Jul 20187:00 amRNSBoard Changes
26th Jun 20181:31 pmRNSCollaboration with Abnova
13th Jun 20187:00 amRNSOutstanding NIPS Solution Provider Award Win
11th Jun 20187:00 amRNSDNA sequencing technology development agreement
7th Jun 20183:44 pmRNSHolding(s) in Company
5th Jun 20187:00 amRNSPremaitha signs partnership agreement in India
4th Jun 201811:05 amRNSHolding(s) in Company
24th May 20187:00 amRNSHolding(s) in Company
18th May 20184:38 pmRNSHolding(s) in Company
18th May 201812:06 pmRNSHolding(s) in Company
18th May 201812:05 pmRNSHolding(s) in Company
18th May 20189:40 amRNSHoldings in Company
15th May 20187:00 amRNSPremaitha expands footprint with new laboratories

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.